Relapsed/Refractory B-Cell LymphomaPhase 1/2NCT03223610Papers
ViPOR Combination
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen
What the film says
CAR T cells transformed B-cell leukemia and lymphoma. For cancers of the T cells themselves, they have been almost impossible to build. The target sits on the weapon: a T cell built to kill anything carrying a T-cell marker kills its neighbors, and itself.
The idea: pick the one marker where that problem can be managed.
CD5 sits on about eighty-five percent of T-cell cancers. Baylor's team found that CAR T cells aimed at CD5 quickly shed their own CD5, so they stop attacking each other and keep hunting the cancer.
MAGENTA, at Houston Methodist and Texas Children's with Rayne Rouce, now makes the cells from a patient's earlier transplant donor, and asks what dose is safe. Public record; not medical advice.
Sources behind this film
Dai Z. Mol Ther, 2021
CAR T for T-cell cancers is hard because the target is on the CAR T cell itself (fratricide)
CAR T for T-cell cancers is hard because the target is on the CAR T cell itself (fratricide); CD5 on ~85% of T-cell malignancies; normal expression restricted to T cells and B1 cells; Now made from the patient's previous transplant donor; lymphodepletion; dose finding; MAGENTA; Houston Methodist and Texas Children's; Rayne Rouce
Mamonkin M. Blood, 2015
CD5 CAR T cells down-regulate their own CD5, limiting fratricide
The drug
Three dose levels will be evaluated: Dose level one: 1×10^7 cells/m2 Dose level two: 5×10^7 cells/m2 Dose level three: 1×10^8 cells/m2
To make the T cells the investigators will take blood from the patient or from the previous bone marrow transplant donor and stimulate it with growth factors to make the T cells grow. To get the CD5 antibody and CD28 to attach to the surface of the T cell, investigators insert the antibody gene into the T cell. This is done with a virus called a retrovirus that has been made for this study and will carry the antibody gene into the T cell.
This virus also helps investigators find the T cells in the patient's blood after they are injected. Because the patient will have received cells with a new gene in them the patient will be followed for a total of 15 years to see if there are any long term side effects of gene transfer.
The study
Patients eligible for this study have a type of blood cancer called T-cell leukemia or lymphoma (lymph gland cancer). The body has different ways of fighting infection and disease. No one way seems perfect for fighting cancers. This research combines two different ways of fighting disease, antibodies and T cells. Antibodies are proteins that protect the body from bacterial and other diseases.
T cells, or T lymphocytes, are special infection-fighting blood cells that can kill other cells including tumor cells. Both antibodies and T cells have shown promise treating patients with cancers, but have not been strong enough to cure most patients. T lymphocytes can kill tumor cells but there normally are not enough of them. Some researchers have taken T cells from a person's blood, grown more in the lab then given them back to the person.
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.